United States Biosimilars Market was valued at USD 6.4 Billion in 2022 and is projected to reach USD 17.8 Billion by 2030, growing at a CAGR of 16.2% from 2024 to 2030.
Start
The U.S. Biosimilars Market Has Seen Exponential Growth, Driven By Increasing Demand From Industries Looking For Cost-Effective Alternatives To Expensive Biologic Treatments. Biosimilars Are Highly Similar Versions Of Already-Approved Biologic Medicines, Offering The Same Efficacy, Safety, And Quality At A Fraction Of The Cost. As The U.S. Healthcare Landscape Shifts Toward More Affordable Solutions, The Role Of Biosimilars In Driving Competition And Lowering Healthcare Costs Cannot Be Overstated.
The U.S. Biosimilars Market Is Influenced By A Number Of Factors, Including The Rising Prevalence Of Chronic Diseases, The Increasing Pressure To Reduce Healthcare Spending, And The Expiration Of Patents For Blockbuster Biologics. For Industries, Biosimilars Provide An Opportunity To Save Significantly On Healthcare Costs While Maintaining Treatment Efficacy. The Healthcare Sector, In Particular, Is Reaping The Benefits As Hospitals, Insurance Companies, And Government Programs Increasingly Prefer Biosimilars Due To Their Lower Costs Compared To Branded Biologics.
Regulatory Frameworks, Such As The Biologics Control Act And The Affordable Care Act, Have Facilitated The Development Of Biosimilars, Ensuring They Meet The Same Rigorous Standards As Their Originators. This Not Only Reassures Healthcare Providers And Patients But Also Paves The Way For Broader Market Adoption. Biosimilars Are Now Available In Therapeutic Areas Such As Oncology, Immunology, And Endocrinology, Making Them A Vital Tool For Treating A Variety Of Medical Conditions.
Industries, Particularly Pharmaceutical And Healthcare Companies, Are Required To Adopt Biosimilars To Stay Competitive And Reduce Costs. Companies Involved In The Development, Manufacturing, And Distribution Of Biosimilars Must Navigate Regulatory Hurdles While Ensuring Their Products Meet Stringent Quality Standards. To Maintain Their Market Share, These Companies Are Focusing On Innovation And Improvements In Biosimilar Production Technologies.
In The U.S., The Growing Demand For Biosimilars Has Been Met With An Influx Of New Products, Increasing Competition And Further Driving Down Costs. For Industries, This Competitive Landscape Is Crucial In Meeting The Healthcare Needs Of A Diverse And Aging Population. As Biosimilars Continue To Play A Critical Role In Reducing The Financial Burden Of Healthcare, The U.S. Biosimilars Market Is Set To Expand Significantly In The Coming Years.
To Further Strengthen This Market, Industries Need To Embrace The Evolution Of Biosimilars And Engage In Continuous Research And Development. By Improving Production Methods And Addressing Challenges Related To Market Access And Adoption, Companies Can Create A Robust Ecosystem For Biosimilars In The U.S., Paving The Way For A Healthier, More Affordable Future.
The U.S. Biosimilars Market Will Continue To Be Shaped By Technological Advancements, Regulatory Policies, And Growing Industry Demand, Transforming The Way Medicines Are Produced And Distributed Across The Healthcare Sector.
Get an In-Depth Research Analysis of the US Biosimilars Market Size And Forecast [2025-2032]
Â
Pfizer
Novartis
Biocon
Biogen
Fresenius Kabi AG
Boehringer Ingelheim
Merck KgaA
Mylan
Eli Lilly
Teva Pharmaceutical
Dr. Reddys Laboratories
Amgen
Celltrion
Samsung Biologics
Roche
Probiomed
Apotex
Chong Kun Dang
JCR Pharmaceuticals
Gan & Lee Pharmaceuticals
Gedeon Richter
Biocad
Coherus Bioscience
Stada Arzneimittel AG
Â
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the US Biosimilars Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the US Biosimilars Market
Monoclonal Antibodies
Insulin
Recombinant Proteins
Growth Hormones
Erythropoietin
Vaccines
Oncology
Diabetes
Autoimmune Diseases
Cardiovascular Diseases
Chronic Kidney Disease
Recombinant DNA Technology
Hybridoma Technology
Protein Engineering
Post-Translational Modifications
Injectable
Oral
Topical
Hospitals
Retail Pharmacies
Online Pharmacies
Clinic Based
Drug Wholesalers
US (United States, US and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Biosimilars Market Research Analysis
1. Introduction of the US Biosimilars Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. US Biosimilars Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. US Biosimilars Market, By Type
6. US Biosimilars Market, By Application
7. US Biosimilars Market, By Geography
US
Europe
Asia Pacific
Rest of the World
8. US Biosimilars Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading US Research and Consulting firm servicing over 5000+ US clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/